Crisaborole

topical · integumentary · immune-hematologic · Transdermal

Crisaborole, a topical compound. Topical PDE4 inhibitor — raises keratinocyte cAMP → reduced inflammatory cytokine release. Approved for… Transdermal half-life 14 h.

Topical PDE4 inhibitor — raises keratinocyte cAMP → reduced inflammatory cytokine release. Approved for atopic dermatitis as steroid-sparing alternative. Application-site burning (~5%) is the most common adverse effect.